TL1A Genotype Selection for Predicting IBD Antibody Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases like inflammatory bowel disease (IBD) are ineffective for many patients, leading to disease worsening and invasive surgeries, while existing genetic analysis methods like GWAS fail to accurately predict therapeutic responses due to limited capture of high-dimensional non-linear polymorphism interactions and biological mechanisms.
Innovation Solution
A machine-learning based approach identifies genotypes associated with TL1A activity or expression that predict therapeutic responses to anti-TL1A inhibitors, utilizing combinations of polymorphisms with both linear and non-linear interactions, enhancing the accuracy of predicting IBD phenotypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If GWAS is used to identify genetic variants associated with IBD, then polymorphisms can be identified, but the accuracy of predicting therapeutic response is insufficient due to failure to capture high-dimensional non-linear polymorphism interactions
Solution Approach 1:
The patent replaces traditional GWAS mechanical analysis with a machine learning-based system that uses algorithms (such as random forests, support vector machines, or neural networks) to process and interpret complex genetic data. This substitution enables the system to capture non-linear polymorphism interactions and high-dimensional patterns that conventional GWAS methods cannot detect, thereby significantly improving the accuracy of predicting therapeutic response to anti-TL1A inhibitors.
Solution Approach 2:
The patent transforms the analysis approach by changing from binary polymorphism association testing to multi-parameter evaluation incorporating multiple polymorphisms simultaneously. The machine learning models process multiple genetic parameters (polymorphisms at different loci) and their interactions as a unified system, enabling accurate prediction of therapeutic response based on the combined effect of genetic variants rather than individual associations.
2Reliability
If conventional anti-inflammatory therapy is used for IBD treatment, then treatment can be administered, but a significant number of patients experience lack of response or loss of response leading to disease worsening
Solution Approach 1:
The patent applies local quality by tailoring treatment decisions to specific patient subgroups based on their genetic profile. Instead of uniform treatment, the system identifies patients with specific polymorphism patterns (such as certain alleles at TNFSF15 locus) who are most likely to respond to anti-TL1A inhibitors. This localized approach ensures that treatment is optimized for each patient's unique genetic characteristics, significantly improving therapeutic response rates.
Solution Approach 2:
The patent implements preliminary action by performing genetic testing and machine learning-based prediction before initiating anti-TL1A inhibitor therapy. The system proactively identifies patients who are most likely to benefit from this specific treatment, allowing clinicians to select the most appropriate therapy in advance rather than relying on trial-and-error approaches after conventional treatments fail.
3Reliability
If surgery is performed for patients not responding to first line therapies, then disease can be managed, but invasive procedures cause post-operative risks for approximately one third of patients
Solution Approach 1:
The patent converts the harmful effect of genetic variability (which causes unpredictable treatment response) into a beneficial tool for treatment selection. By analyzing polymorphisms and using machine learning to predict response, the system transforms what was previously a source of treatment failure into a guide for selecting the most effective therapy, thereby preventing the need for surgery in many patients and eliminating associated surgical risks.
Data Source
AI summary
Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.